Well, hopefully Amgen is excited about NEO and just takes us out before AXAL approval..................ready to get out of this basement......ransom has been paid, new CEO/CMO............so much ahead of us to move the needle forward
Blue, I agree with you but actually the NEO trial will comprise multiple indications. 4, I think. I’m also not sure that we want license HOT indications to multiple BPs, because it makes the eventual buyout less attractive. Although it could set up a nice competition. I’m on the fence on that issue.
Market Data 
Markets 
AI
